Merck scraps Keytruda lung cancer trial adding Bristol Myers’ Yervoy. What about the Opdivo combo?
Merck’s Keytruda is without doubt the king in previously untreated non-small cell lung cancer, but the company wanted to see whether adding another immuno-oncology agent from rival Bristol Myers Squibb would offer additional benefit. Turns out, doing that adds more harm and no good. Merck decided to stop adding Bristol Myers’ CTLA-4 inhibitor Yervoy to Keytruda in… Read More »
